Facing a critical US launch for an innovative chronic knee pain therapy, our client, a global healthcare leader, needed a partner to develop a go-to-market and access strategy grounded in real-world insight. Princeton Biopartners was selected to design a comprehensive commercialization roadmap that would accelerate uptake, secure payer buy-in, and build lasting market advantage. Princeton Biopartners helped pave our client’s way for a robust market launch and sustained growth, achieving 25% market share growth and a 40% increase in key opinion leader (KOL) endorsements and clinician adoption rates.
Challenges
- Crowded Market, High Bar for Differentiation: Competing against entrenched treatments covering 70% of market share required a standout value proposition.
- Outcome-Based Reimbursement Pressure: Demonstrating superiority in real-world effectiveness was key to unlocking favorable payer positioning.
- Complex Regulatory Dynamics: The drug class faced a high reclassification risk; strong trial design and messaging were essential.
- Shifting HCP Engagement Models: A post-COVID drop in in-person visits demanded adaptive strategies leveraging digital channels and remote education.
Approach
Our team designed a robust plan across commercial, market access, and medical affairs activities to ensure a successful launch and drive sustained performance:
Market Landscape Analysis
- Market Share: Leveraged competitor insights to assess current brand positioning and identify whitespace opportunities in chronic knee pain.
- Market Size: Quantified the total addressable population using claims data and epidemiological sources to estimate commercial potential.
- Market Trends: Identified shifts in patient and provider behavior post-COVID, including the move toward non-opioid and digital-first treatment models.
- Unmet Needs: Mapped gaps in treatment satisfaction, focusing on product usability and patient adherence as key differentiators.
Payer Strategy & Segmentation
- Payer Archetypes: Profiled major payer segments across commercial and public channels to tailor messaging and contracting approaches.
- Price Benchmarking: Analyzed pricing of analogs to inform viable launch pricing bands and assess reimbursement risk.
- Pre-approval Engagement: Designed an early engagement strategy including payer education materials and advisory boards.
- Access Strategy: Built a value-based narrative aligned to both clinical trial results and anticipated real-world outcomes to secure formulary access.
Integrated Launch Planning
- Cross-functional Planning: Coordinated inputs across medical, market access, and commercial teams to ensure a unified launch strategy.
- Launch Readiness: Facilitated monthly launch excellence workshops to validate progress, refine timelines, and align leadership.
- Strategic Embedding: Integrated the launch roadmap into the client’s digital platform for real-time visibility and responsiveness.
- Performance Monitoring: Defined key launch metrics and success thresholds to guide early post-launch course correction.
Impact
Our recommendations effectively highlighted that the drug’s innovative mode of action and ease of use are key levers to differentiate in the market. We strategically repositioned the product away from crowded efficacy narratives toward its ease-of-use and rapid impact, insights validated through clinician interviews and claims analytics.
Key outcomes included:
- Market Penetration: Achieved 25% market share growth by clearly differentiating the product in a crowded marketplace.
- Physician Endorsements: Realized a 35% increase in key opinion leader (KOL) endorsements and clinician adoption rates, strengthening the product’s credibility.
- Payer Engagement: Secured new payer agreements and improved reimbursement rates, resulting in expanded coverage.
- Strategic Impact: Reinforced product positioning based on clinical innovation, setting the stage for long-term competitive advantage.
Collectively, these results underscored the success of our strategy, paving the way for a robust market launch and sustained growth.
Expertise Utilised
- Strategic KOL Network Access: Leveraged our extensive relationships with therapeutic area leaders to guide positioning, validate unmet need, and support peer-to-peer advocacy.
- US Claims Data Analytics Platform: Accessed >85% of national claims data to uncover prescribing patterns, identify high-opportunity geographies, and validate target population estimates.
- Payer Archetyping & Segmentation Framework: Applied our proprietary models to identify payer behaviors, inform contracting strategies, and forecast access barriers.
- Cross-functional Launch Planning Toolkit: Used our integrated templates and playbooks to align commercial, access, and medical teams-accelerating decision-making and reducing launch friction.
Contact us to learn how we can drive sustainable improvements for your organization.